Latin America: An Evolving Regulatory Environment September 15, Mapi 2015, All Rights Reserved

Similar documents
The 3E Principle of Outsourcing

Introduction to Health Economics and Outcomes Research (HEOR) for Writers

Take a Course of Action.

European Patients Academy (EUPATI) Update

...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS

Clinical Research Professionals

Retrospective Chart Review Studies

CQA Consultant of HVCC, Hilversum, the Netherlands. Coaching of auditors on various levels is an on-going activity.

Confronting the Challenges of Rare Disease:

Q Manpower. Employment Outlook Survey Global. A Manpower Research Report

European Patients Academy on Therapeutic Innovation

Registries for Evaluating Patient Outcomes:

HOW EBAY IS BRIDGING THE GLOBAL TALENT GAP BY ENGAGING ACADEMIA. SABINE RIOUFOL - APRIL 14 th, 2016

Novartis Business Services HR University Relations. Regulatory Affairs. Graduate & Postgraduate Program

Pharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist

NANCI A. HAYWARD North Springs Drive Dunwoody, Georgia

Q Manpower. Employment Outlook Survey Global. A Manpower Research Report

The European network evaluation of the PHAR QA framework of competences for...

Q Manpower. Employment Outlook Survey Global. A Manpower Research Report

Santander Latin American Conference. Cancun, January 2009

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION)

Analysis Group, Inc. Health Economics, Outcomes Research, and Epidemiology Practice Areas

Specialty Pharmacy How is Traditional Pharmacy Practice Positioned

Duke-Margolis Center: Overview And High Priority Projects in Biomedical Innovation and Payment

New Alignments in Data-Driven Care Coordination & Access for Specialty Products: Insights from the DIMENSIONS Report

1st Maghreb Regulatory Conference

EUPATI PROJECT: EXECUTIVE SUMMARY

Policies Approved by the 2017 ASHP House of Delegates

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018

GCP Inspection by PMDA

Physician / Investigator. Over 40% of clinical trial data are entered into health record and EDC 1

Addendum to ICH E6 (R2)

MSc REGULATORY AFFAIRS MEDICINES / MEDICAL DEVICES PROSPECTUS

Health Technology Assessment (HTA) Good Practices & Principles FIFARMA, I. Government s cost containment measures: current status & issues

Targeted technology and data management solutions for observational studies

BUILDING BRIDGES. LatAm Startups is proud to announce its 2017 initiatives:

Work plan for GCP Inspectors Working Group for 2018

Information Brochure Professional Certificate in Pharmacovigilance

POST-LAUNCH DEMANDS: Dr Thomas Lönngren ISPOR Content

Introduction To Medpace & Clinical Research Overview

A guide to PDUFA V. Focus US update. Regulatory Rapporteur Vol 9, No 11, November 2012

HTAi: A Global Collaboration. Laura Sampietro-Colom, MD, PhD Deputy Director Innovation. Hospital Clinic Barcelona HTAi Immediate Past President

TABLE OF CONTENTS. 1.2 Market Overview Introduction Industry Drivers Market Size 1-5

Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland

Luke Timmerman. Timmerman Report, Moderator

Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess.

ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY

Access Telefonica. (Making the right connections in the post-telefonica-digital era) May 27 th - 28 th Sales lead

Real World Evidence in Europe

Pharmacovigilance & Managed Care Pharmacy. Issues for Medication Safety in Korea

CPRD Clinical Practice Research Datalink

Cross-Border Enrollment of Rare Disease Patients

2017 Oncology Insights

Trading our way out of trouble. Liberalisation and trade past, current and future policy trends

Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013

Pharmacovigilance: The patient s Perspective. Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA

Q Manpower. Employment Outlook Survey Global. A Manpower Research Report

Background and Issues. Aim of the Workshop Analysis Of Effectiveness And Costeffectiveness. Outline. Defining a Registry

Measures of impact of pharmacovigilance processes (3.3)

Mission, Vision & Strategic Plan

How to Get the Business Started?

Thank you for joining ISMPP U today! The program will begin promptly at 11:00 am EST

Potential of the use of electronic patient information for clinical research in the pharmaceutical industry

Determining and Reporting Adverse Events vs. Product Complaints

Regulatory Affairs Outsourcing

Regulatory Updates Health Sciences Authority Singapore

our soul telefónica in 2006

VIRTUAL CONFERENCE DIVERSITY AND CULTURAL COMPETENCE TUESDAY, DECEMBER 2, 2014

Why aren t we all using Real-World Evidence if it is so insightful and powerful? Because it is difficult to generate. Introducing E360 by IMS Health

A CASE STUDY: PARTNERING WITH COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS TO INCREASE CAPACITY AND SUPPORT GROWTH March 14, 2017

Training components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA

European network of paediatric research (Enpr-EMA)

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility

Training & Resources for Clinical Research Professionals

1 st Regional Conference on Regulatory Harmonisation

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

Open Telefonica: Open Innovation Experiences in Telefonica I+D (the R&D Unit of Telefónica Group)

Overview ICH GCP E6(R2) Integrated Addendum

First inspection of a Legal Representative in the EU by local authority

Clinical Nurse Leader (CNL ) Certification Exam. Subdomain Weights for the CNL Certification Examination Blueprint (effective February 2012)

IIS Sponsor Reference Guide

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE

EXECUTIVE EDUCATION in Life Sciences

SEEKING PATIENT PERSPECTIVES IN CLINICAL TRIAL DESIGN AMY FROMENT, GLOBAL FEASIBILITY OPERATIONS DIR THE PATIENT S VOICE 2017

Telefónica vision around EU Industrial Policies

Lessons from the EMA Patient Registries Initiative

PORTUGUESE PHARMACEUTICAL SOCIETY POLITICAL AND ECONOMICAL FRAMEWORK

September 16 th, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

THE GLOBAL PARTNERSHIP FOR BUSINESS AND BIODIVERSITY Information Newsletter Volume 2, Issue I February 2014

Section Title. Prescribing competency framework Catherine Picton, Lead author

Pharmacovigilance Office of Product Review

Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) Vision: Healthcare without infection

Future of Community Healthcare Providers. Author: Mr. Raj Shah, CEO, CTIS Inc.

7 th European Forum for Qualified Person for Pharmacovigilance (QPPV)

Core Purpose the organization s reason for being and Core Values essential and enduring principles that guide the behavior of an organization.

ONESOURCE Indirect Tax Reporting 6

Turbocharging Mexico s Innovation Stephen Ezell VP, Global Innovation Policy ITIF. Mexico Innovation Week March 30, 2017

IMDRF FINAL DOCUMENT. Title: Strategic Assessment of Electronic Submission Messaging Formats

PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI

Outsourcing biopharmaceuticals manufacturing Best practices when working with external supply partners

Transcription:

Latin America: An Evolving Regulatory Environment September 15, 2015 Mapi 2015, All Rights Reserved

Upcoming Live Webinar Event: Key Information Featured Webinar Hosts Silvia Bendiner Director of Strategic Regulatory Affairs and Life Sciences, Mapi Group Fernando Ferrer Life Sciences Expert in Global and Latin American Business Expansion and Growth; Mapi Group Consultant and Guest Co-Host ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Important Webinar Information Tuesday, September 15th, 2015 10:00 am, EDT (New York, GMT-04:00) 3:00 pm, BST (London, GMT+01:00) 4:00 pm, CEST (Paris, GMT+02:00) Webinar Registration Page (Share this with Colleagues!): http://webinars.mapigroup.com/latin-american-regulatory-affairs 2

Webinar Host Silvia Bendiner Director, Regulatory Affairs Latin America Ms. Bendiner has over 25 years of life sciences experience, including pharmaceuticals, biotechnology, medical devices, generics, nutraceuticals, nutritional supplements, translational therapy, herbal medicines and biologics. Ms. Bendiner joined OptumInsight (acquired by Mapi Group in December, 2014) at a time when the Company was expanding its expertise in the region which was directly driven by a strong interest and demand from Optum clients. Silvia brings a wealth of experience and a clear understanding of specifics of growing successful regulatory operations and understands the challenges of expansion in Latin America. Ms. Bendiner is an expert in the development of Regulatory and Marketing strategies for drugs and devices within international markets. Her expertise in Mexico, Puerto Rico and Latin America ranges from regulatory submissions to preparing market feasibility studies to negotiating distribution and partnership agreements. She has worked with small, mid-size businesses (including start-up companies) in developing business, commercial and operation plans, supported both pre and post product launch activities in various therapeutic areas. She has worked in the area of Clinical Development and Business Development with inlicensing expertise across Mexico and Latin America. Ms. Bendiner holds a Bachelors Degree in Languages and Sciences, and started her professional career as a simultaneous translator and interpreter in the US and Mexico. She is bilingual in English and Spanish, fluent in Italian and German with conversational skills in French and Portuguese. 3

Webinar Host Fernando Ferrer Managing Partner, Multinational Partnerships LLC Regulatory Services Consultant, Mapi Group Fernando Ferrer is a proven business leader in life science with experience across different corporate and cultural environments, and speaker in industry related events. Mr. Ferrer is based in the US, and due to his professional career he lived also in Spain, Switzerland, Argentina and Brazil, and besides his global roles, has had experience working directly with 30+ countries. Ferrer began his professional career in the chemical-pharmaceutical Swiss company Roche (F. Hoffmann-La Roche A.G.), where he had Latin American and global roles for diverse business units while living in different countries. Heading up his latest enterprise, Multinational Partnerships, LLC, he is focused on strategic planning and business expansion of life science organizations across Latin-American markets, and the development and management of business alliances among multinational and Latin American organizations for both, in business-to-consumer (B2C), and business-tobusiness (B2B) markets. In his academic role at RVCC, he serves as adjunct professor of management, international business and global strategic management. 4

Webinar Description This webinar will provide a current overview of the Latin American Regulatory environment with country specific regulatory requirements. The main focus will be on Argentina, Brazil, Mexico and Colombia. The presenter will share regulatory strategies, procedures and techniques explaining the utilization of ICH standards and compliance requirements for elaborating and processing regulatory submission dossiers for successful Market Authorization approval across the region. We encourage a Q&A session for sharing experiences and tips to successfully navigate the Latin American regulatory environment. 5

Key Discussion Points The Business opportunities of Life-Science in Latin America. The current business approach Overview of the Regulatory Process across the LATAM region Strategic Regulatory Filing The Do s and Don ts A practical approach Recommendations for inclusion of LATAM as part of a company s global regulatory strategy Question and Answer (Q&A) Session 6

What You Will Learn How to elaborate a Latin American regulatory dossier implementing a road map country/regional specific. Gain insights of the Do s and Dont s for dossier preparation, dossier filing activities while meeting the expectations of local Health Authorities to obtain Market Authorization approval. 7

About Mapi Group Founded 40 Years Ago Pioneered many of the practices that are now standard in the industry: Patient centered research PROs Linguistic Validation Acquired Registrat in 2010 pioneered registries Established Mapi Research Trust non profit information clearing house for researchers Services RWE conducting post approval studies Epidemiology consulting Patient Centered Outcomes Research Language Services Health Economics and Outcome Research Strategic Market Access 8

Market Adoption Peak Phase I - III 9

Mapi Group is uniquely able to do the things that CROs cannot... Pharma identifies Endpoint Strategy Pharma identifies COA options and begins licensing discussions Patient-Centered Outcomes Services Language Services Health Economic Outcomes Research Services Value Dossier and Strategic Market Access Services Real World Evidence Services 10

From Integrated to Integral The world s largest independent company exclusively focused on Health Research and Commercialization offering aligned services to support: Market Authorization Market Access Market Adoption 11

Integrating services to meet demand, Strategic Regulatory Services (SRS) Strategic Regulatory Services brings global leadership and deep regulatory knowledge through integrated consulting focused on maximizing value through its traditional regulatory consulting, pharmacovigilance services, clinical manufacturing and quality audits across the life sciences market. Regulatory Comprehensive knowledge and ability to navigate the complex regulatory/clinical approval process across international jurisdictions Quality Client assessment and improvement to meet safety requirements and ongoing monitoring of safety measurements Pharmacovigilance Industry knowledge and research to maintain compliance in an ever-changing environment Full service functional outsourced Regulatory group Global submissions and maintenance of marketed products Chemistry, manufacturing and controls (CMC) services Regulatory operations (traditional and electronic submissions and publishing) Global agency liaison and meeting preparation Information services (Freedom Of Information, literature searches, etc.) Quality system design and execution (pharma, biologics, devices) Due diligence audits & assessments Remediation assistance Training GMP, GCP Audits Full service functional outsourced Pharmacovigilance/Drug Safety department European Qualified Person for Pharmacovigilance Risk management plan development Adverse signal detection and management Preparation of regulatory reports Training Call Center 12

Health Research and Commercialization Mapi services support the acceleration of Treatment peak revenue Post approval requirements Payers & Endorsement bodies Advocates, prescribers & patients Regulatory requirements unlock potential The key to success is a strategy for regulatory commitments and commercialization Mapi delivers commercial value from your research investment 13

Mapi Health Economics & Outcomes Research (HEOR) Industry.Leadership Value Identification 35+ HTA environment reviews Insights into HTA decision making for biosimilars 35+ Global Value Dossiers Value Generation 150+ systematic literature reviews in a variety of therapeutic areas 85+ network meta-analyses / indirect treatment comparisons 80+ economic models: 18+ core cost-effectiveness models 47+ country adaptations 80+ HRQoL, PRO and ClinRO scales developed, including: 10+ simultaneous development / 20+ scales for clinical practice 20+ PRO Endpoint strategy conducted 20+ phase III trials PRO endpoints analyzed 100+ scales psychometrically validated 200+ publications in HEOR & PRO for the past 5 Value Communications 200+ submissions 45+ submissions to NICE, CVZ, AWMSG, G-BA & SMC 150+ submissions to HAS 20+ countries worldwide 39 dossiers intended to list a MEDICAL DEVICE 25+ budget impact models and country adaptations 14

Mapi Real-World Evidence (RWE) Industry Leadership Late-Phase Studies & Real World Evidence Registries Expanded access Post-authorization Safety Studies (PASS) Post-authorization Effectiveness Studies (PAES) Product Utilization Studies Observational/Non-interventional Studies Phase IV Studies Global Study Operations Patient Retention & Management Chart Review Survey Risk Management & Safety RMPs & REMS Regulatory Responses Aggregated Safety Reports Epidemiology Market Forecasts Literature Reviews Protocol Development Strategy & Consulting Training 15

Thank you Additional Questions? Ask our Webinar Hosts directly! Silvia Bendiner, Webinar Host: Phone + 1 321 972 2082 sbendiner@mapigroup.com Fernando Ferrer, Webinar Host: Phone + 1 908 326 6417 - info@multinationalpartnerships.com Mapi 2015, All Rights Reserved